Halyard Health Inc (HYH) is Trading Higher on Unusual Volume for December 21

Equities Staff |

Halyard Health Inc (HYH) experienced unusually high volume on Dec. 21, as the stock gained 0.9% to a closing price of $33.74. The stock saw 962,391 shares trade hands over the course of the day on 4,685 trades. Given that the stock’s average daily volume over the last month has been 356,418 shares a day, this represents a pretty substantial spike over the norm.

Halyard Health Inc has a P/B ratio of 1.51. The stock has traded between $50.92 and $26.58 over the last 52-weeks, its 50-day SMA is now $30.85, and its 200-day SMA $37.97.

Halyard Health Inc provides healthcare supplies and solutions that targets the prevention of healthcare associated infections. The Company's business segments include surgical & infection prevention and medical devices.

Headquartered in Alpharetta, GA, Halyard Health Inc has 12,000 employees and is currently under the leadership of CEO Robert E. Abernathy.

For a complete fundamental analysis analysis of Halyard Health Inc, check out Equities.com’s Stock Valuation Analysis report for HYH. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.


The Russell 3000 is not well known outside the world of finance, but it’s one of the strongest indices out there for getting a broad sense of the stock market. Unlike the better-known Dow Jones Industrial Average or S&P 500, membership on the Russell 3000 isn’t selected by committee. It’s simply the 3,000 most valuable companies in the country.

With 3,000 stocks making up the index, it gives a broad look at the markets, including the small-and mid-cap companies that aren’t on the Dow or the S&P 500. And with a rules-based system for determining membership, there’s no bias that could potentially limit membership. That’s why many financial professionals will turn to the Russell 3000 long before the better-known indices when trying to take the temperature of the market.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

iPRO Network, LLC

We provide the platform, tools, and resources to empower individuals and professionals to market desirable goods and services to the public, taking the place of traditional methods of commerce.

The Green Organic Dutchman

The Green Organic Dutchman Ltd. ("TGOD") produces farm grown, organic cannabis for medical use. The company grows its high quality organic cannabis in small batches using craft growing, all natural…